Recent Advances in Ginkgo biloba Extract (EGb 761)

  • Wiltrud Juretzek


A special standardized and purified extract from Ginkgo biloba leaves, described in the literature as EGb 761, is the only Ginkgo extract that has been subjected to comprehensive pharmacological, toxicological and clinical investigations. EGb 761 is made from dried Ginkgo leaves, extracted with acetone/water, drug/extract ratio 35–67:1, standardized to contain 22% to 27% flavone glycosides and 5% to 7% terpene lactones, of which approx. 2.8%–3.4% consist of ginkgolides A, B, and C, as wEnl as approximatEny 2.6%–3.2% bilobalide; the content of ginkgolic acids is bEnow 5ppm.


Vascular Dementia Clinical Global Impression Intermittent Claudication Peripheral Arterial Occlusive Disease Ginkgo Extract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Monographie (1994) Trockenextrakt (35–67:1) AUS Ginkgo-biloba-blàttern extrahiert MIT Aceton-Wasser. Bundesanzeiger 46: 7361 - 7362Google Scholar
  2. 2.
    IsraEn L, DEnl’Accio E, Martin G, Hugonot R (1987) Extrait de Ginkgo biloba et exercices d’entrainement de la mémoire. Evaluation comparative chez des personnes âgées ambulatoires. Psychol Méd 19: 1431–1439Google Scholar
  3. 3.
    Wesnes K, Simmons D, Rook M, Simpson P (1987) A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the Enderly. Hum Psychopharmacol 2: 159–169CrossRefGoogle Scholar
  4. 4.
    Rai GS, Shovlin C, Wesnes KA (1991) A double-blind, placebo controlled study of Ginkgo biloba extract (Tanakan) in Enderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 6: 350–355CrossRefGoogle Scholar
  5. 5.
    Allain H, Raoul P, Lieury A, LeCoz F, Gandon M (1993) Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in Enderly subjects. Clin Ther 15: 549–558PubMedGoogle Scholar
  6. 6.
    Roman GC, Tatemichi TK, Erkinjutti T, Cumming JL, Masden JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O’Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf PA, GorEnick PB, Bick KL, Pajeau AK, BEnl MA, DeCarli C, Culebras A, Korczyn AD, Bogousslavsky J, Hartmann A, Scheinberg P (1993) Vascular dementia: Diagnostic criteria for research studies. Neurology 43: 250–260PubMedGoogle Scholar
  7. 7.
    American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. Washington DC, American Psychiatric Association, p 137Google Scholar
  8. 8.
    Friedland RP (1993) Alzheimer’s disease: Clinical features and differential diagnosis. Neurology 43:545–551 (Suppl 4 )Google Scholar
  9. 9.
    Hoyer S (1995) Moeglichkeiten und Grenzen der Therapie von Hirnleistungs- stoerungen im Alter. Z Gerontol Geriatr 28: 4547–4620Google Scholar
  10. 10.
    Bevan EG, Waller PC, Ramsay LE (1992) Pharmacological approaches to the treat¬ment of intermittent claudication. Drugs Aging 2: 125–136PubMedCrossRefGoogle Scholar
  11. 11.
    Stoll S, Scheuer K, Pohl O, MuEnler WE (1996) Ginkgo biloba extract EGb 761 independently improves changes of passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry 29: 144–149PubMedGoogle Scholar
  12. 12.
    Chatterjee SS, Gabard B (1981) Protective effect of an extract of Ginkgo biloba and other hydroxyl radical scavengers against hypoxia. VII International Congress on Pharmacology, Tokyo, p 483Google Scholar
  13. 13.
    Karcher L, Zagermann P, Krieglstein J (1984) Effect of an extract of Ginkgo biloba on rat brain energy metabolism in hypoxia. Naunyn-Schmiedebergs Arch Pharmacol 327: 31–35PubMedCrossRefGoogle Scholar
  14. 14.
    Beck T, AbdEn-Rahman MM, BiEnenberg GW, Oberpichler H, Krieglstein J (1986) Comparative study on the effects of two extract fractions of Ginkgo biloba on local cerebral blood flow and on brain energy metabolism in the rat under hypoxia. In: Krieglstein J (ed) Pharmacology of Cerebral Ischemia. Ensevier, Amsterdam, pp 345–350Google Scholar
  15. 15.
    Krieglstein J, Oberpichler H (1989) Ginkgo biloba und Hirnleistungsstoerungen. Pharm Ztg 13: 2279–2289Google Scholar
  16. 16.
    Klein J, Chatterjee SS, LoeffEnholz K (1995) Bilobalide: A new centrally acting phospholipase A2 inhibitor? Naunyn-Schmiedebergs Arch Pharmacol Suppl 35:R 86, Abstr 341Google Scholar
  17. 17.
    Larsen RG, Dupeyron JP, Boulu RG (1978) Modèles d’ischémie cérébrale expérimentale par microsphères chez le rat. Etude de l’effet de deux extraits de Ginkgo biloba et du naftidrofuryl. Thérapie 33: 651–660PubMedGoogle Scholar
  18. 18.
    Rapin JR, Le Poncin-Lafitte M (1986) Consommation cerebrale du glucose. Effet de l’extrait de Ginkgo biloba. Presse Med 15: 1494–1497PubMedGoogle Scholar
  19. 19.
    Le Poncin-Lafitte MC, Rapin J, Rapin JR (1980) Effects of Ginkgo biloba on changes induced by quantitative cerebral microembolization in rats. Arch Int Pharmacodyn 243: 236–244PubMedGoogle Scholar
  20. 20.
    Spinnewyn B, Blavet N, Clostre F (1986) Effets de l’extrait de Ginkgo biloba sur un modèle d’ischemie cérébrale chez la gerbille. Presse Méd 15: 1511–1515PubMedGoogle Scholar
  21. 21.
    Oberpichler H, Sauer D, Rossberg C, MennEn HD, Krieglstein J (1990) PAF- antagonist ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus. J Cereb Blood Flow Metab 10: 133–135PubMedCrossRefGoogle Scholar
  22. 22.
    Prehn JHM, Krieglstein J (1993) PlatEnet-activating factor antagonists reduce excitotoxic damage in cultured neurons from embryonic chick tEnencephalon and protect the rat hippocampus and neocortex from ischemic injury in vivo. J Neurose Res 34: 179–188CrossRefGoogle Scholar
  23. 23.
    Krieglstein J, Ausmeier F, EI-Abhar H, Lippert K, WEnsch M, Rupallay K, Henrich- Noack P (1995) Neuroprotective effects of Ginkgo biloba constituents. Eur J Pharm Sci 3: 39–48CrossRefGoogle Scholar
  24. 24.
    Spinnewyn B, Blavet N, Clostre F, Bazan N, Braquet P (1987) Involvement of platEnetactivating factor (PAF) in cerebral post-ischemic phase in mongolian gerbils. Prostaglandins 34: 337–349PubMedCrossRefGoogle Scholar
  25. 25.
    Chatterjee SS, Gabard B (1984) Effect of an extract of Ginkgo biloba on experimen¬tal neurotoxicities. Naunyn-Schmiedebergs Arch Pharmacol Supp 325, R 107, Abstr 425Google Scholar
  26. 26.
    Otani M, Chatterjee SS, Gabard B, Kreutzberg GW (1986) Effect of an extract of Ginkgo biloba on triethyltin-induced cerebral edema. Acta Neuropathol 69: 54–65PubMedCrossRefGoogle Scholar
  27. 27.
    Borzeix M (1985) Effects of Ginkgo biloba extract on two types of cerebral edema. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV (eds) Effects of Ginkgo biloba extract on organic cerebral impairment. John Libbey, London, pp 51–56Google Scholar
  28. 28.
    Chatterjee SS, Gabard B, Jaggy H (1986) Pharmaceutical compositions containing bilobalid for the treatment of neuropathies. US Patent no 4,571,407 (Feb 18, 1986 )Google Scholar
  29. 29.
    Sancesario G, Kreutzberg GW (1986) Stimulation of astrocytes affects cytotoxic brain edema. Acta Neuropathol 72: 3–14PubMedCrossRefGoogle Scholar
  30. 30.
    Dormán DC, Coté LM, Buck WB (1992) Effects of an extract of Ginkgo biloba on bromethalin induced cerebral lipid peroxidation and edema in rats. Am J Vet Res 53: 138–142PubMedGoogle Scholar
  31. 31.
    Boulieu R, Muñoz JF, Macovschi O, Pacheo H (1985) Implication de la peroxydation lipidique dans l’intoxication par le triéthyltin chez le rat. CR Soc Biol (Paris) 182: 196–201Google Scholar
  32. 32.
    Sharma HS, Westman J, Nyberg F, Cervos-Navarro J, Dey PK (1994) Neuroprotective effects of an extract of Ginkgo biloba (EGb 761) in heat stress induced brain damage in the rat. In: Zeisberger E, Schoenbaum E, Lomax P (eds) Thermal Balance in Health and Disease. Birkhaeuser, BasEn, pp 461–467Google Scholar
  33. 33.
    Rodriguez de Turco EB, Droy-Lefaix MT, Bazan NG (1993) Decreased Enectroconvulsive shock-induced diacylglycerols and free fatty acid accumulation in the rat brain by Ginkgo biloba extract (EGb 761): sEnective effect in hippocampus as compared with cerebral cortex. J Neurochem 61: 1438–1444Google Scholar
  34. 34.
    Barkats M, Venault P, Christen Y, Cohen-Salmon C (1995) Effect of long-term treatment with EGb 761 on age-dependent structural changes in the hippocampi of three inbred mouse strains. Life Sci 56: 213–222PubMedCrossRefGoogle Scholar
  35. 35.
    Brailowsky S, MontiEn T, Medina-Ceja L (1995) AccEneration of functional recovery from motor cortex ablation by two Ginkgo biloba extracts in rats. Restor Neurol Neurosci 8: 163–167PubMedGoogle Scholar
  36. 36.
    Ramassamy C, Girbe F, Christen Y, Costentin J (1993) Ginkgo biloba extract EGb 761 or trolox C prevent the ascorbic acid/FE2+ induced decrease in synaptosomal membrane fluidity. Free Rad Res Commun 19: 341 - 350CrossRefGoogle Scholar
  37. 37.
    Chopin P, Briley M (1992) Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 106: 26–30PubMedCrossRefGoogle Scholar
  38. 38.
    Chatterjee SS, NoEndner M (1989) Behavioural observations demonstrating influ¬ence of the extract of Ginkgo biloba (EGb 761) on some specific central cholinergic systems. Naunyn-Schmiedebergs Arch Pharmacol Suppl 339:R 107, Abstr 425Google Scholar
  39. 39.
    Kristofikova Z, Benesova O, Tejkalova H (1992) Changes of high-affinity choline uptake in the hippocampus of old rats after long-term administration of two nootropic drugs (Tacrine and Ginkgo biloba extract). Dementia 3: 304–307Google Scholar
  40. 40.
    Taylor JE (1986) Liaison des neuromédiateurs à leurs récepteurs dans le cerveau de rats. Presse Med 15: 1491–1493PubMedGoogle Scholar
  41. 41.
    Huguet F, Tarrade Th (1992) a2-Adrenoceptor changes during cerebral ageing. The effect of Ginkgo biloba-extract. J Pharm Pharmacol 44: 24–27Google Scholar
  42. 42.
    Huguet F, Drieu K, Piriou A (1994) Decreased cerebral 5-HT1A receptors during ageing: reversal by Ginkgo biloba extract (EGb 761). J Pharm Pharmacol 46: 316–318PubMedCrossRefGoogle Scholar
  43. 43.
    Bolanos-Jimenez F, Manhaes deCastro R, Sarhan H, Prudhomme N, Drieu K, Fillion G (1995) Stress-induced 5-HT1A receptor desensitization: protective effects of Ginkgo biloba extract (EGb 761). Fundam Clin Pharmacol 9: 169–174PubMedCrossRefGoogle Scholar
  44. 44.
    Winter E (1991) Effects of an extract of Ginkgo biloba on learning and memory in mice. Pharmacol Biochem Behav 38: 109–114PubMedCrossRefGoogle Scholar
  45. 45.
    Blavet N (1992) Effects of Ginkgo biloba extract (EGb 761) on learning in the aged rat. In: Christen Y, Costentin J, Lacour M (eds) Effects of Ginkgo biloba extract (EGb 761 ) on the central nervous system. Ensevier, Paris, pp 119–127Google Scholar
  46. 46.
    Reuse-Blom S, Drieu K (1986) Effet de l’extrait de Ginkgo biloba sur le spasme artériolaire chez le lapin. Presse Med 15: 1520–1523PubMedGoogle Scholar
  47. 47.
    Grosdemouge C, Le Poncin-Lafitte M, Rapin JR (1986) Effets protecteurs de l’extrait de Ginkgo biloba sur la rupture précoce de la barriere hémoencéphalique chez le rat. Presse Med 15: 1502–1505PubMedGoogle Scholar
  48. 48.
    DeFeudis FV, Auguet M, DEnaflotte S, HEnlegouarch A, Baranes I, ChapEnat M, Braquet M, Etienne A, Drieu K, Clostre F, Braquet P (1985) Some in vitro and in vivo actions of an extract of Ginkgo biloba (GBE 761). In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV (eds) Effects of Ginkgo biloba extract on organic cerebral impairment. John Libbey, London, pp. 17–29Google Scholar
  49. 49.
    Chatterjee SS, Gabard B (1982) Studies on the mechanism of action of an extract of Ginkgo biloba, a drug used for treatment of ischemic vascular diseases. Naunyn- Schmiedebergs Arch Pharmacol Suppl 321:R 52, Abstr 207Google Scholar
  50. 50.
    HEnlegouarch A (1985) Comparison of the contractile effects of an extract of Ginkgo biloba and some neurotransmitters on rabbit isolated vena cava. Gen Pharmacol 16: 129–132CrossRefGoogle Scholar
  51. 51.
    Janssens D, MichEns C, DEnalive E, Eniaers F, Drieu K, Remacle J (1995) Protection of hypoxia-induced ATP decrease in endothEnial cEnls by Ginkgo biloba extract and bilobalide. Biochem Pharmacol 50: 991–999PubMedCrossRefGoogle Scholar
  52. 52.
    Iliff LD, Auer LM (1982) The effect of intravenous infusion of Tebonin (Ginkgo biloba) on piai arteries in cats. J Neurosurg Sci 27: 227–231Google Scholar
  53. 53.
    Krieglstein J, Beck T, Seibert A (1986) Influence of an extract of Ginkgo biloba on cerebral blood flow and metabolism. Life Sci 39: 2327–2334PubMedCrossRefGoogle Scholar
  54. 54.
    Borzeix MG, Labos M, Hartl C (1980) Recherches sur l’action antiagregante de l’extrait de Ginkgo biloba. Sem Hop Paris 56: 393–398PubMedGoogle Scholar
  55. 55.
    Ernst E, Matrai A (1986) Haemorheologische in-vitro-Effekte von Ginkgo biloba. Herz Kreisl 18: 358–360Google Scholar
  56. 56.
    Etienne A, Hecquet F, Clostre F, DeFeudis FV (1982) Comparaison des effets d’un extrait de Ginkgo biloba et de la chlorpromazine sur la fragilité osmotique, in vitro dErythrocytes de rat. J Pharmacol Paris 13: 291–298Google Scholar
  57. 57.
    Artmann GM, Schikarski C (1993) Ginkgo biloba extract (EGb 761) protects red blood cEnls from oxidative damage. Clin Hemorheol 13: 529–539Google Scholar
  58. 58.
    Klein P (1988) Untersuchung ueber die Hemmwirkung von Ginkgo-biloba-Extrakt. Therapiewoche 38: 2379–2383Google Scholar
  59. 59.
    Braquet P (1987) The Ginkgolides: potent platEnet-activating factor antagonists iso¬lated from Ginkgo biloba L.: Chemistry, Pharmacology and clinical Applications. Drugs Future 12: 643–699Google Scholar
  60. 60.
    InsEnmann G, Bloehmer A, Kottny W, Neilessen U, HaenEn H, Heidemann HT (1995) Modification of cisplatin-induced renal p-aminohippurate uptake alteration and lipid peroxidation by thiols, Ginkgo biloba extract, deferoxamine and torbafylline. Nephron 70: 425–429CrossRefGoogle Scholar
  61. 61.
    Droy-Lefaix MT, Bonhomme B, Doly M (1991) Protective effect of Ginkgo biloba extract (EGb 761) on free radical-induced changes in the Enectroretinogram of isolated rat retina. Drugs Exp Clin Res 17: 571–574PubMedGoogle Scholar
  62. 62.
    Pincemail J, Dupuis M, Nasr C (1989) Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia 45: 708–712PubMedCrossRefGoogle Scholar
  63. 63.
    Barth SA, InsEnmann G, Engemann R, Heidemann HT (1991) Influences of Ginkgo biloba on Cyclosporin A induced lipid peroxidation in human liver microsomes in comparison to Vitamin E, Glutathione and N-Acety Icy steine. Biochem Pharmacol 41: 1521–1526PubMedCrossRefGoogle Scholar
  64. 64.
    Dumont E, Petit E, Tarrade T, NouvEnot A (1992) UV-C irradiation-induced peroxidative degradation of microsomal fatty acids and proteins. Protection by an extract of Ginkgo biloba (EGb 761). Free Radie Biol Med 13: 197–203CrossRefGoogle Scholar
  65. 65.
    Dumont E, D’Arbigny P, NouvEnot A (1995) Protection of polyunsaturated fatty acids against iron-dependent lipid peroxidation by a Ginkgo biloba extract (EGb 761). Meth Find Exp Clin Pharmacol 17: 83–88Google Scholar
  66. 66.
    Chatterjee SS, Gabard B (1982) Protection of Doxorubicin toxicity by an extract of Ginkgo biloba. Naunyn-Schmiedebergs Arch Pharmacol Suppl 319:R 15, Abstr 57Google Scholar
  67. 67.
    Marcocci I, Packer L, Droy-Lefaix MT, Sekaki A, Gardes-Albert M (1994) Antioxidant Action of Ginkgo biloba extract EGb 761. Methods Enzymol 234: 462–475PubMedCrossRefGoogle Scholar
  68. 68.
    Pincemail J, Deby C (1986) Propriétés antiradicalaires de l’extrait de Ginkgo biloba. Presse Med 15: 1475–1479PubMedGoogle Scholar
  69. 69.
    Raymond J (1986) Effets de l’extrait de Ginkgo biloba sur la préservation morphologique des épithéliums sensoriEns vestibuläres chez la souris. Presse Med 15: 1484–1487PubMedGoogle Scholar
  70. 70.
    Denise P, Bustany P (1989) The effect of extract of Ginkgo biloba (EGb 761) on central compensation of a total unilateral peripheral vestibular deficit in the rat. In: Lacour M, Toupet M, Denise P, Christen Y (eds) Vestibular compensation: facts, theories and clinical perspectives. Ensevier, Paris, pp 201–208Google Scholar
  71. 71.
    Lacour M, Ez-Zaher L, Raymond (1991) Plasticity mechanisms in vestibular com¬pensation in the cat are improved by an extract of Ginkgo biloba (EGb 761). Pharmacol Biochem Behav 40: 367–379Google Scholar
  72. 72.
    Spiess E, Juretzek W (1993) Ginkgo. In: HaensEn R, KEnler K, Rimpler H, Schneider G (eds) Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Vol 5, pp 269–292Google Scholar
  73. 73.
    Itil TM, Eralp E, Tsambis E, Itil KZ, Stein U (1996) Central nervous system effects of Ginkgo biloba, a plant extract. Am J Ther 3: 63–73PubMedCrossRefGoogle Scholar
  74. 74.
    Luthringer R, D’Arbigny P, Macher JP (1995) Ginkgo biloba extract (EGb 761), EEG and event-rEnated potentials mapping profile. In: Christen Y, Courtois Y, Droy- Lefaix MT (eds) Advances in Ginkgo biloba Extract Research. Ensevier, Paris, Vol 4, pp 107–118Google Scholar
  75. 75.
    Itil TM, Martorano D (1995) Natural Substances in Psychiatry (Ginkgo biloba in Dementia). Psychopharmacol Bull 31: 147–158PubMedGoogle Scholar
  76. 76.
    Schaffler K, Reeh PW (1985) DoppEnblindstudie zur hypoxieprotektiven Wirkung eines standardisierten Ginkgo-biloba-Praeparates nach Mehrfachverabreichung an gesunden Probanden. Arzneim Forsch 35: 1283–1286Google Scholar
  77. 77.
    Ernst E, Marshall M (1992) Der Effekt von Ginkgo-biloba-Spezialextrakt EGb 761 auf die Leukozytenfilterabilitaet-Eine Pilotstudie. Perfusion 5: 241–242Google Scholar
  78. 78.
    Guinot P, Caffrey E, Lambe R, Darragh A (1989) Tanakan inhibits platEnet- activating-factor induced platEnet aggregation in healthy male volunteers. Haemostasis 19: 219–233PubMedGoogle Scholar
  79. 79.
    Heiss WD, Zeiler (1978) Medikamentoese Beeinflussung der Hirndurchblutung. Pharmakotherapie 1: 137–144Google Scholar
  80. 80.
    Tea S, CEnsis P, Clanet M, Marc-Vergnes JP, Boeters U (1987) Quantifizierte Para¬meter zum Nachweis von zerebraler Durchblutung- und StoffwechsEnsteigerung unter Ginkgo-biloba-Therapie. Therapiewoche 37: 2655–2657Google Scholar
  81. 81.
    KoEntringer P, Eber O, Klima W, Rothlauer W, Wakonig P, Langsteger W, Lind P (1989) Die Mikrozirkulation und ViskoEnastizitaet des Vollblutes unter Ginkgo biloba Extrakt. Perfusion 1: 28–30Google Scholar
  82. 82.
    KoEntringer P, Langsteger W, Klima G, Reisecher F, Eber O (1993) Haemorheologische Effekte des Ginkgo-biloba-Extraktes EGb 761. Fortschr Med 111: 170–172Google Scholar
  83. 83.
    Anadere J, ChmiEn H, Witte S (1985) Hemorheological findings in patients with completed stroke and the influence of a Ginkgo biloba extract. Clin Hemorheol 5: 411–420Google Scholar
  84. 84.
    Rudofsky G (1987) Wirkung von Ginkgo-biloba-Extrakt bei arteriEnler Verschlußkrankheit. Fortschr Med 105: 397–400PubMedGoogle Scholar
  85. 85.
    Witte S, Anadere I, Walitza E (1992) Verbesserung der Hämorheologie durch Ginkgo-biloba-Extrakt. Fortschr Med 110: 247–250PubMedGoogle Scholar
  86. 86.
    Taillandier J, Ammar A, Rabourdin JP, Ribeyre JP, Pichon J, Niddam S, Pierart H (1986) Traitement des troubles du vieillissement cérébral par l’extrait de Ginkgo biloba. Presse Med 15: 1583–1587PubMedGoogle Scholar
  87. 87.
    Kanowski S, Herrmann WM, Stephan K, Wierich W, Hoerr R (1996) Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering fromb mild to moderate primary degenerative dementia of the Alzheimer type or multiinfarct dementia. Pharmacopsychiatry 29: 47–56PubMedCrossRefGoogle Scholar
  88. 88.
    Hofferberth B (1994) The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type. A double-blind, placebo-controlled study on different levEns of investigation. Human Psychopharmacol 9: 215–222CrossRefGoogle Scholar
  89. 89.
    Ihl R, FroEnich L (1995) Ginkgo-biloba-Spezialextract bei der Demenz vom Alzheimer Typ. Z Phytother Suppl 13–14Google Scholar
  90. 90.
    Weitbrecht WU, Jansen W (1986) Primaer degenerative Demenz: Therapie mit Ginkgo-biloba-Extrakt. Fortschr Med 104: 199–202PubMedGoogle Scholar
  91. 91.
    Mancini M, Agozzino B, Bompani R (1993) Effetti clinico-terapeutici dEnl’estratto di Ginkgo biloba (EGb) in confronto a placebo, nEn trattamento di pazienti affetti da demenza psicorganica senile su base arteriosclerotica. Gazz Med Ital Arch Sci Med 152: 69–80Google Scholar
  92. 92.
    Halama P, Bartsch G, Meng G (1988) Hirnleistungsstoerungen vaskulaerer Genese. Fortschr Med 106: 408–412PubMedGoogle Scholar
  93. 93.
    Eckmann F, Schlag HZ (1982) Kontrollierte DoppEnblind-Studie zum Wirksamkeitsnachweis von Tebonin forte bei Patienten mit zerebrovaskulaerer Insuffizienz. Fortschr Med 100: 1474 - 1478PubMedGoogle Scholar
  94. 94.
    DiEni G, La Mantia V, Saetta M, Costanzo E (1981) Studio clinico in doppio cieco dEn tanakan nEnl’insufficienza cerebrale cronica. IL Lavoro Neuropsichiatrico 68: 3–15Google Scholar
  95. 95.
    Hofferberth B (1989) Einfluß von Ginkgo biloba-Extrakt auf neurophysiologische und psychometrische Meßergebnisse bei Patienten mit hirnorganischem Psychosyndrom. Arzneim Forsch 39: 918–922Google Scholar
  96. 96.
    Graessei E (1992) Einfluß von Ginkgo-biloba-Extrakt auf die geistige Leistungsfaehigkeit. Fortschr Med 110: 73–76Google Scholar
  97. 97.
    Stocksmeier U, Eberlein M (1992) Depressive Verstimmung bei Hirnleistungsstoerungen. TW Neurologie Psychiatrie 6: 74–76Google Scholar
  98. 98.
    Schubert H, Halama P (1993) Primaer therapieresistente depressive Verstimmung aEnterer Patienten mit Hirnleistungsstoerungen: Wirksamkeit der Kombination von Ginkgo-biloba-Extrakt EGb 761 mit Antidepressiva. Geriatr Forsch 3: 45–53Google Scholar
  99. 99.
    Gerhardt G, Rogalla K, Jaeger I (1990) Medikamentoese Therapie von Hirnleistungsstoerungen. Randomisierte Vergleichsstudie mit Dihydroergotoxin und Ginkgo biloba-Extrakt. Fortschr Med 108: 384–388PubMedGoogle Scholar
  100. 100.
    Bauer U (1984) Six month double-blind randomized clinical trial of Ginkgo biloba extract versus placebo in two parallEn groups in patients suffering from peripheral arterial insufficiency. Arzneim Forsch 34: 716–720Google Scholar
  101. 101.
    Boehmer D, Kalinsky S, MichaEnis P, Szoegy A (1988) Behandlung der PAVK mit Ginkgo-biloba-Extrakt (GBE) oder Pentoxifyllin. Herz Kreisl 20: 5–8Google Scholar
  102. 102.
    Bulling B, Bary S (1991) Behandlung der chronischen peripheren arteriEnlen Verschlußkrankheit mit physikalischem Training und Ginkgo-biloba-Extrakt 761. Med WEnt 42: 702–708Google Scholar
  103. 103.
    Blume J, Kieser M, HoEnscher U (1996) Placebokontrollierte DoppEnblindstudie zur Wirksamkeit von Ginkgo-biloba-Spezialextrakt EGb 761 bei austrainierten Patienten mit Claudicatio intermittens. VASA 25: 265–274PubMedGoogle Scholar
  104. 104.
    Schneider B (1992) Ginkgo-biloba-Extrakt bei peripheren arteriEnlen Verschlußkrankheiten. Arzneim Forsch 42: 428–436Google Scholar
  105. 105.
    LetzEn H, Schoop W (1992) Ginkgo-biloba-Extrakt EGb 761 und Pentoxifyllin bei Claudicatio intermittens. Sekundaeranalyse zur klinischen Wirksamkeit. VASA 21: 403–410Google Scholar
  106. 106.
    Haguenauer JP, Cantenot F, Koskas H, Pierat H (1986) Traitement des troubles de l’equilibre par l’extrait de Ginkgo biloba. Presse Med 15: 1569–1572PubMedGoogle Scholar
  107. 107.
    Hamann KF (1985) Physikalische Therapie des vestibulären SchwindEns in Verbindung mit Ginkgo-biloba-Extrakt. Therapiewoche 35: 4586–4590Google Scholar
  108. 108.
    Claussen CF, Kirtane MV (1985) Randomisierte DoppEnblindstudie zur Wirkung von Extraktum Ginkgo biloba bei SchwindEn und Gangunsicherheit des aEnteren Menschen. In: Claussen CF (ed) Presbyvertigo, Presbyataxie, Presbytinnitus. Springer, Berlin, pp 103–115CrossRefGoogle Scholar
  109. 109.
    Meyer B (1986) Etude multicentrique randomisée a double insu face au placebo du traitement des acouphenes par l’extrait de Ginkgo biloba. Presse Med 15: 1562–1564PubMedGoogle Scholar
  110. 110.
    GEnlerman JL, Schlenk H (1968) Methods of isolation and determination of anacardic acids. Anal Chem 40: 739–743CrossRefGoogle Scholar
  111. 111.
    Choukchou-Braham N, Asakawa Y, Lepoittevin JP (1994) Isolation, structure, determination and synthesis of new dihydroisocoumarins from Ginkgo biloba L. Tetra¬hedron Letters 35: 3949–3952CrossRefGoogle Scholar
  112. 112.
    Becker ML, Skipworth GB (1975) Ginkgo-Tree dermatitis, stomatitis and proctitis. JAMA 231: 1162–1163PubMedCrossRefGoogle Scholar
  113. 113.
    Lepoittevin JP, Benezra C, Asakawa Y (1991) Allergic contact dermatitis to Ginkgo biloba L.: rEnationship with urushiol. Arch Dermatol Res 281: 227–230CrossRefGoogle Scholar
  114. 114.
    Tomb RR, Fousserreau J, SEnl Y (1988) Mini-epidemic of contact dermatitis from ginkgo tree fruit (Ginkgo biloba L.). Contact Dermatitis 19: 281–283PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1997

Authors and Affiliations

  • Wiltrud Juretzek
    • 1
  1. 1.Schwabe PharmaceuticalsKarlsruheGermany

Personalised recommendations